$PRTA
PROTHENA CORP PUBLIC LTD CO Stock $prta

$prta Overview Financials Valuation SEC Filings Company Website

2020 Q4 Form 10-Q Financial Statement

#000155905320000040 Filed on November 04, 2020

Income Statement

Concept	2020 Q4	2020 Q3	2019 Q3
Revenue	$360.0K	$157.0K	$205.0K
YoY Change	40.63%	-23.41%	-19.61%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$9.910M	$9.400M	$8.690M
YoY Change	22.95%	8.17%	-5.95%
% of Gross Profit
Research & Development	$20.76M	$21.61M	$12.49M
YoY Change	34.2%	73.03%	-32.56%
% of Gross Profit
Depreciation & Amortization	$360.0K	$400.0K	$400.0K
YoY Change	-10.0%	0.0%	-50.0%
% of Gross Profit
Operating Expenses	$30.67M	$31.00M	$21.18M
YoY Change	30.34%	46.4%	-13.84%
Operating Profit		-$30.85M	-$20.97M
YoY Change		47.08%	-13.78%
Interest Expense	$10.00K	$40.00K	$2.030M
YoY Change	-99.36%	-98.03%	156.96%
% of Operating Profit
Other Income/Expense, Net	-$70.00K	$54.00K	$1.992M
YoY Change	-450.0%	-97.29%	174.38%
Pretax Income	-$30.36M	-$30.79M	-$18.98M
YoY Change	39.97%	62.23%	-19.57%
Income Tax	$350.0K	-$215.0K	$468.0K
% Of Pretax Income
Net Earnings	-$30.72M	-$30.58M	-$19.45M
YoY Change	42.51%	57.22%	-20.81%
Net Earnings / Revenue	-8532.22%	-19475.8%	-9486.83%
Basic Earnings Per Share	-$0.77	-$0.77	-$0.49
Diluted Earnings Per Share	-$0.77	-$0.77	-$0.49
COMMON SHARES
Basic Shares Outstanding	39.92M shares	39.92M shares	39.90M shares
Diluted Shares Outstanding		39.92M shares

Balance Sheet

Concept	2020 Q4	2020 Q3	2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$295.4M	$314.5M	$390.3M
YoY Change	-21.37%	-19.42%	-13.55%
Cash & Equivalents	$295.4M	$314.5M	$390.3M
Short-Term Investments
Other Short-Term Assets	$3.900M	$6.000M	$3.148M
YoY Change	50.93%	90.6%	-41.7%
Inventory
Prepaid Expenses
Receivables	$15.00K	$22.00K
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$299.3M	$320.5M	$409.2M
YoY Change	-20.9%	-21.68%	-10.44%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.551M	$2.899M	$4.245M
YoY Change	-34.15%	-31.71%	-91.98%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$333.0K	$327.0K	$677.0K
YoY Change	-69.31%	-51.7%	34.86%
Total Long-Term Assets	$33.69M	$35.30M	$41.69M
YoY Change	-17.61%	-15.33%	-38.43%
TOTAL ASSETS
Total Short-Term Assets	$299.3M	$320.5M	$409.2M
Total Long-Term Assets	$33.69M	$35.30M	$41.69M
Total Assets	$333.0M	$355.8M	$450.9M
YoY Change	-20.58%	-21.09%	-14.05%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.117M	$2.810M	$2.418M
YoY Change	231.48%	16.21%	-46.09%
Accrued Expenses	$20.50M	$17.50M	$12.90M
YoY Change	30.57%	35.66%	29.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due			$0.00
YoY Change			-100.0%
Total Short-Term Liabilities	$25.85M	$21.72M	$31.76M
YoY Change	45.92%	-31.61%	34.44%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$553.0K	$553.0K	$553.0K
YoY Change	0.0%	0.0%	0.0%
Total Long-Term Liabilities	$123.1M	$124.5M	$130.0M
YoY Change	-4.29%	-4.16%	-19.46%
TOTAL LIABILITIES
Total Short-Term Liabilities	$25.85M	$21.72M	$31.76M
Total Long-Term Liabilities	$123.1M	$124.5M	$130.0M
Total Liabilities	$149.0M	$146.3M	$161.7M
YoY Change	1.79%	-9.55%	-12.57%
SHAREHOLDERS EQUITY
Retained Earnings	-$783.0M	-$752.3M	-$650.3M
YoY Change	16.54%	15.68%	13.0%
Common Stock	$399.0K	$399.0K	$399.0K
YoY Change	0.0%	0.0%	0.25%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$184.0M	$209.5M	$289.2M
YoY Change
Total Liabilities & Shareholders Equity	$333.0M	$355.8M	$450.9M
YoY Change	-20.58%	-21.09%	-14.05%

Cashflow Statement

Concept	2020 Q4	2020 Q3	2019 Q3
OPERATING ACTIVITIES
Net Income	-$30.72M	-$30.58M	-$19.45M
YoY Change	42.51%	57.22%	-20.81%
Depreciation, Depletion And Amortization	$360.0K	$400.0K	$400.0K
YoY Change	-10.0%	0.0%	-50.0%
Cash From Operating Activities	-$19.09M	-$19.41M	-$8.940M
YoY Change	31.75%	117.11%	-73.37%
INVESTING ACTIVITIES
Capital Expenditures	-$50.00K	-$80.00K	-$250.0K
YoY Change	-54.55%	-68.0%	66.67%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$0.00
YoY Change
Cash From Investing Activities	-$50.00K	-$80.00K	-$250.0K
YoY Change	-54.55%	-68.0%	66.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	70.00K	0.000
YoY Change	-100.0%		-100.0%
NET CHANGE
Cash From Operating Activities	-19.09M	-19.41M	-8.940M
Cash From Investing Activities	-50.00K	-80.00K	-250.0K
Cash From Financing Activities	0.000	70.00K	0.000
Net Change In Cash	-19.14M	-19.42M	-9.190M
YoY Change	31.19%	111.32%	-73.51%
FREE CASH FLOW
Cash From Operating Activities	-$19.09M	-$19.41M	-$8.940M
Capital Expenditures	-$50.00K	-$80.00K	-$250.0K
Free Cash Flow	-$19.04M	-$19.33M	-$8.690M
YoY Change	32.41%	122.44%	-74.0%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2019Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.49
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.02
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001559053
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Document Period End Date DocumentPeriodEndDate	2020-09-30
	dei	Document Transition Report DocumentTransitionReport	false
CY2016Q1	prta	Buildtosuit Lease Termof Contract BuildtosuitLeaseTermofContract	P7Y9M30D
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Entity File Number EntityFileNumber	001-35676
	dei	Entity Registrant Name EntityRegistrantName	PROTHENA CORPORATION PUBLIC LIMITED COMPANY
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	L2
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1111119
	dei	Entity Address Address Line1 EntityAddressAddressLine1	77 Sir John Rogerson’s Quay, Block C
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Grand Canal Docklands
	dei	Entity Address City Or Town EntityAddressCityOrTown	Dublin 2,
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	D02 T804,
	dei	Entity Address Country EntityAddressCountry	IE
	dei	Country Region CountryRegion	353
	dei	City Area Code CityAreaCode	1
	dei	Local Phone Number LocalPhoneNumber	236-2500
	dei	Security12b Title Security12bTitle	Ordinary Shares, par value $0.01 per share
	dei	Trading Symbol TradingSymbol	PRTA
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2020Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	39921413	shares
CY2020Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	314525000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	375723000	USD
CY2020Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	22000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	68000	USD
CY2020Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4586000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2584000	USD
CY2020Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	1352000	USD
CY2019Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	0	USD
CY2020Q3	us-gaap	Assets Current AssetsCurrent	320485000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	378375000	USD
CY2020Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2899000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3874000	USD
CY2020Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	19197000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	23274000	USD
CY2020Q3	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	11524000	USD
CY2019Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	9956000	USD
CY2020Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1352000	USD
CY2019Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	2704000	USD
CY2020Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	327000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1085000	USD
CY2020Q3	us-gaap	Assets Noncurrent AssetsNoncurrent	35299000	USD
CY2019Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	40893000	USD
CY2020Q3	us-gaap	Assets Assets	355784000	USD
CY2019Q4	us-gaap	Assets Assets	419268000	USD
CY2020Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	2810000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1242000	USD
CY2020Q3	prta	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	7617000	USD
CY2019Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	128633000	USD
CY2019Q4	prta	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	5826000	USD
CY2020Q3	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	258000	USD
CY2019Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	5000	USD
CY2020Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5408000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5101000	USD
CY2020Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	5629000	USD
CY2019Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	5540000	USD
CY2020Q3	us-gaap	Liabilities Current LiabilitiesCurrent	21722000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	17714000	USD
CY2020Q3	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	110242000	USD
CY2019Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	110242000	USD
CY2020Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	13753000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	17838000	USD
CY2020Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	553000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	553000	USD
CY2020Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	124548000	USD
CY2020Q3	us-gaap	Liabilities Liabilities	146270000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	146347000	USD
CY2020Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	prta	Deferred Shares Par Value DeferredSharesParValue	22
CY2020Q3	prta	Deferred Shares Par Value DeferredSharesParValue	22
CY2020Q3	prta	Deferred Shares Value DeferredSharesValue	0	USD
CY2019Q4	prta	Deferred Shares Value DeferredSharesValue	0	USD
CY2019Q4	prta	Deferred Shares Shares Authorized DeferredSharesSharesAuthorized	10000	shares
CY2020Q3	prta	Deferred Shares Shares Authorized DeferredSharesSharesAuthorized	10000	shares
CY2020Q3	prta	Deferred Shares Shares Authorized DeferredSharesSharesAuthorized	10000	shares
CY2019Q4	prta	Deferred Shares Shares Authorized DeferredSharesSharesAuthorized	10000	shares
CY2020Q3	prta	Deferred Shares Share Outstanding DeferredSharesShareOutstanding	0	shares
CY2020Q3	prta	Deferred Shares Share Outstanding DeferredSharesShareOutstanding	0	shares
CY2020Q3	prta	Deferred Shares Share Issued DeferredSharesShareIssued	0	shares
CY2020Q3	prta	Deferred Shares Share Issued DeferredSharesShareIssued	0	shares
CY2019Q4	prta	Deferred Shares Share Outstanding DeferredSharesShareOutstanding	0	shares
CY2019Q4	prta	Deferred Shares Share Outstanding DeferredSharesShareOutstanding	0	shares
CY2019Q4	prta	Deferred Shares Share Issued DeferredSharesShareIssued	0	shares
CY2019Q4	prta	Deferred Shares Share Issued DeferredSharesShareIssued	0	shares
CY2020Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020Q3	us-gaap	Common Stock Value CommonStockValue	399000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	399000	USD
CY2020Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2020Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2020Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	39921413	shares
CY2020Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	39921413	shares
CY2020Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	39921413	shares
CY2020Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	39921413	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	39898561	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	39898561	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	39898561	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	39898561	shares
CY2020Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	961428000	USD
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	944407000	USD
CY2020Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-752313000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-671885000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	209514000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	272921000	USD
CY2020Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	355784000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	419268000	USD
CY2020Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	157000	USD
CY2019Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	205000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	493000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	558000	USD
CY2020Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	21605000	USD
CY2019Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12486000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	54124000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	35365000	USD
CY2020Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9398000	USD
CY2019Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8691000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	28795000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	27677000	USD
CY2020Q3	us-gaap	Restructuring Costs RestructuringCosts	0	USD
CY2019Q3	us-gaap	Restructuring Costs RestructuringCosts	0	USD
	us-gaap	Restructuring Costs RestructuringCosts	0	USD
	us-gaap	Restructuring Costs RestructuringCosts	-61000	USD
CY2020Q3	us-gaap	Operating Expenses OperatingExpenses	31003000	USD
CY2019Q3	us-gaap	Operating Expenses OperatingExpenses	21177000	USD
	us-gaap	Operating Expenses OperatingExpenses	82919000	USD
	us-gaap	Operating Expenses OperatingExpenses	62981000	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-30846000	USD
CY2019Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-20972000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-82426000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-62423000	USD
CY2020Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	43000	USD
CY2019Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	2034000	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	1359000	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	6634000	USD
CY2020Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	11000	USD
CY2019Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-42000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	176000	USD
CY2020Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	54000	USD
CY2019Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1992000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1362000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	6810000	USD
CY2020Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-30792000	USD
CY2019Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-18980000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-81064000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-55613000	USD
CY2020Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-215000	USD
CY2019Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	468000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	510000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-636000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-19448000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-56123000	USD
CY2020Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.77
CY2019Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.49
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.02
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.41
CY2020Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	39917000	shares
CY2019Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	39897000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	39912000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	39877000	shares
	us-gaap	Net Income Loss NetIncomeLoss	-56123000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1152000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1164000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	16806000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	18298000	USD
	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-1568000	USD
	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-751000	USD
	prta	Amortizationofrightofuseasset Amortizationofrightofuseasset	4077000	USD
	prta	Amortizationofrightofuseasset Amortizationofrightofuseasset	3923000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-46000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	1244000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	15033000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	3669000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	13993000	USD
	us-gaap	Increase Decrease In Restructuring Reserve IncreaseDecreaseInRestructuringReserve	0	USD
	us-gaap	Increase Decrease In Restructuring Reserve IncreaseDecreaseInRestructuringReserve	-461000	USD
	prta	Increase Decreasein Operating Lease Liability IncreaseDecreaseinOperatingLeaseLiability	3778000	USD
	prta	Increase Decreasein Operating Lease Liability IncreaseDecreaseinOperatingLeaseLiability	3493000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-61268000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-38481000	USD
	us-gaap	Payments To Acquire Machinery And Equipment PaymentsToAcquireMachineryAndEquipment	145000	USD
	us-gaap	Payments To Acquire Machinery And Equipment PaymentsToAcquireMachineryAndEquipment	449000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	8000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-145000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-441000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	215000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	215000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	215000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	215000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-61198000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-38707000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	378427000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	431715000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	317229000	USD
CY2019Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	393008000	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	672000	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1200000	USD
	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	37000	USD
	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	82000	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	28530000	USD
	prta	Reductionof Buildtosuit Lease Obligation ReductionofBuildtosuitLeaseObligation	0	USD
	prta	Reductionof Buildtosuit Lease Obligation ReductionofBuildtosuitLeaseObligation	51546000	USD
	prta	Reductionof Amounts Capitalized Under Buildtosuit Lease Transaction ReductionofAmountsCapitalizedUnderBuildtosuitLeaseTransaction	0	USD
	prta	Reductionof Amounts Capitalized Under Buildtosuit Lease Transaction ReductionofAmountsCapitalizedUnderBuildtosuitLeaseTransaction	46760000	USD
	prta	Reductionof Capitalized Interest During Construction Periodfor Buildtosuit Lease Transaction ReductionofCapitalizedInterestDuringConstructionPeriodforBuildtosuitLeaseTransaction	0	USD
	prta	Reductionof Capitalized Interest During Construction Periodfor Buildtosuit Lease Transaction ReductionofCapitalizedInterestDuringConstructionPeriodforBuildtosuitLeaseTransaction	1099000	USD
CY2020Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	314525000	USD
CY2019Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	390304000	USD
CY2020Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	1352000	USD
CY2019Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	0	USD
CY2020Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1352000	USD
CY2019Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	2704000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	317229000	USD
CY2019Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	393008000	USD
CY2020Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	234444000	USD
CY2020Q3	us-gaap	Share Based Compensation ShareBasedCompensation	5583000	USD
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	5583000	USD
CY2020Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	64000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-30577000	USD
CY2020Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	209514000	USD
CY2019Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	302807000	USD
CY2019Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	5816000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-19448000	USD
CY2019Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	289175000	USD
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	272921000	USD
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	16806000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	215000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-80428000	USD
CY2020Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	209514000	USD
CY2018Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	322998000	USD
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	18298000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	215000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-56123000	USD
CY2019Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	289175000	USD
CY2020Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-752300000	USD
CY2020Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	314500000	USD
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Condensed Consolidated Financial Statements in conformity with GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates, including critical accounting policies or estimates related to revenue recognition, share-based compensation, research and development expenses and leases. The Company bases its estimates on historical experience and on various other market specific and other relevant assumptions that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Because of the uncertainties inherent in such estimates, actual results may differ materially from these estimates.</span></div>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment and Concentration of Risks</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates in one segment. The Company’s chief operating decision maker (the “CODM”), its Chief Executive Officer, manages the Company’s operations on a consolidated basis for purposes of allocating resources. When evaluating the Company’s financial performance, the CODM reviews all financial information on a consolidated basis.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and cash equivalents and accounts receivable. The Company places its cash equivalents with high credit quality financial institutions and, by policy, limits the amount of credit exposure with any one financial institution. Deposits held with banks may exceed the amount of insurance provided on such deposits. The Company has not experienced any losses on its deposits of cash and cash equivalents and its credit risk exposure is up to the extent recorded on the Company's Consolidated Balance Sheet.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The receivables recorded in the Condensed Consolidated Balance Sheet include amounts due from a Roche entity located in Switzerland. Collaboration revenue recorded in the Condensed Consolidated Statements of Operations consists of reimbursement from Roche for research and development services. The Company's credit risk exposure is up to the extent recorded on the Company's Condensed Consolidated Balance Sheet.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As of September 30, 2020, $2.9 million of the Company’s property and equipment, net were held in the U.S. and none were in Ireland. As of December 31, 2019, $3.9 million of the Company's property and equipment, net were held in the U.S. and none were in Ireland. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not own or operate facilities for the manufacture, packaging, labeling, storage, testing or distribution of nonclinical or clinical supplies of any of its drug candidates. The Company instead contracts with and relies on third-parties to manufacture, package, label, store, test and distribute all preclinical development and clinical supplies of our drug candidates, and it plans to continue to do so for the foreseeable future. The Company also relies on third-party consultants to assist in managing these third-parties and assist with its manufacturing strategy.</span></div>
CY2020Q3	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	9343000	USD
CY2019Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	9312000	USD
CY2020Q3	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	1261000	USD
CY2019Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	1261000	USD
CY2020Q3	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	1444000	USD
CY2019Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	1308000	USD
CY2020Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	12048000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	11881000	USD
CY2020Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	9149000	USD
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	8007000	USD
CY2020Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2899000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3874000	USD
CY2020Q3	us-gaap	Depreciation Depreciation	400000	USD
	us-gaap	Depreciation Depreciation	1200000	USD
CY2019Q3	us-gaap	Depreciation Depreciation	400000	USD
	us-gaap	Depreciation Depreciation	1200000	USD
CY2020Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4467000	USD
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4818000	USD
CY2020Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	547000	USD
CY2019Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	400000	USD
CY2020Q3	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	615000	USD
CY2019Q4	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	322000	USD
CY2020Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	5629000	USD
CY2019Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	5540000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-19448000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-56123000	USD
CY2020Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	39917000	shares
CY2019Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	39897000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	39912000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	39877000	shares
CY2020Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.77
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.41
CY2020Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	1600000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	4800000	USD
CY2019Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	1600000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	4800000	USD
CY2020Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	1500000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	4500000	USD
CY2019Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	1500000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	4300000	USD
CY2016Q1	prta	Operating Lease Area OperatingLeaseArea	128751	sqft
CY2020Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y3M
CY2016Q1	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2023-12-31
CY2016Q2	us-gaap	Capital Leases Future Minimum Payments Due CapitalLeasesFutureMinimumPaymentsDue	39200000	USD
CY2016Q4	prta	Operating Leases Improvement Allowance OperatingLeasesImprovementAllowance	14200000	USD
CY2020Q3	us-gaap	Restricted Cash RestrictedCash	2700000	USD
CY2018Q3	prta	Operating Leases Sublease Rentals Areaof Sublease Rental OperatingLeasesSubleaseRentalsAreaofSubleaseRental	46641	sqft
CY2020Q3	us-gaap	Sublease Income SubleaseIncome	700000	USD
	us-gaap	Sublease Income SubleaseIncome	2200000	USD
CY2019Q3	us-gaap	Sublease Income SubleaseIncome	700000	USD
	us-gaap	Sublease Income SubleaseIncome	2200000	USD
CY2018Q3	prta	Subleaserentals Annual Base Rent Initial Amount SubleaserentalsAnnualBaseRentInitialAmount	2700000	USD
CY2018Q3	prta	Operating Leases Sublease Rentals Percent Annual Rent Increase OperatingLeasesSubleaseRentalsPercentAnnualRentIncrease	0.035
CY2018Q3	prta	Operating Leases Sublease Rentals Termof Contract OperatingLeasesSubleaseRentalsTermofContract	P5Y2M12D
CY2018Q3	prta	Operating Leases Sublease Rentals Percentof Rental Gain Attributableto Sublandlord OperatingLeasesSubleaseRentalsPercentofRentalGainAttributabletoSublandlord	0.50
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	1529000	USD
CY2020Q3	us-gaap	Lessor Operating Lease Payments To Be Received Remainder Of Fiscal Year LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear	727000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	6191000	USD
CY2020Q3	us-gaap	Lessor Operating Lease Payments To Be Received Two Years LessorOperatingLeasePaymentsToBeReceivedTwoYears	2944000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	6350000	USD
CY2020Q3	us-gaap	Lessor Operating Lease Payments To Be Received Three Years LessorOperatingLeasePaymentsToBeReceivedThreeYears	3047000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	6535000	USD
CY2020Q3	us-gaap	Lessor Operating Lease Payments To Be Received Four Years LessorOperatingLeasePaymentsToBeReceivedFourYears	3019000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	20605000	USD
CY2020Q3	us-gaap	Lessor Operating Lease Payments To Be Received LessorOperatingLeasePaymentsToBeReceived	9737000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1411000	USD
CY2020Q3	prta	Lessee Operating Lease Liability Nominal Payments LesseeOperatingLeaseLiabilityNominalPayments	33000	USD
CY2020Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	19161000	USD
CY2020Q3	us-gaap	Purchase Obligation PurchaseObligation	9200000	USD
CY2020Q3	us-gaap	Purchase Obligation PurchaseObligation	9155000	USD
CY2020Q3	us-gaap	Purchase Obligation Future Minimum Payments Remainder Of Fiscal Year PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear	9155000	USD
CY2020Q3	us-gaap	Purchase Obligation Due In Second Year PurchaseObligationDueInSecondYear	0	USD
CY2020Q3	us-gaap	Purchase Obligation Due In Third Year PurchaseObligationDueInThirdYear	0	USD
CY2020Q3	us-gaap	Purchase Obligation Due In Fourth Year PurchaseObligationDueInFourthYear	0	USD
CY2020Q3	us-gaap	Purchase Obligation Due In Fifth Year PurchaseObligationDueInFifthYear	0	USD
CY2020Q3	us-gaap	Purchase Obligation Due After Fifth Year PurchaseObligationDueAfterFifthYear	0	USD
CY2020Q3	prta	Purchaseand Contractual Obligation Total PurchaseandContractualObligationTotal	9970000	USD
CY2020Q3	prta	Purchaseand Contractual Obligation Remainderof Fiscal Year PurchaseandContractualObligationRemainderofFiscalYear	9280000	USD
CY2020Q3	prta	Purchaseand Contractual Obligation Duein Second Year PurchaseandContractualObligationDueinSecondYear	85000	USD
CY2020Q3	prta	Purchaseand Contractual Obligation Duein Third Year PurchaseandContractualObligationDueinThirdYear	70000	USD
CY2020Q3	prta	Purchaseand Contractual Obligation Duein Fourth Year PurchaseandContractualObligationDueinFourthYear	70000	USD
CY2020Q3	prta	Purchaseand Contractual Obligation Duein Fifth Year PurchaseandContractualObligationDueinFifthYear	60000	USD
CY2020Q3	prta	Purchaseand Contractual Obligation Due After Fifth Year PurchaseandContractualObligationDueAfterFifthYear	405000	USD
CY2020Q3	prta	Collaboration Revenue CollaborationRevenue	200000	USD
	prta	Collaboration Revenue CollaborationRevenue	400000	USD
CY2019Q3	prta	Collaboration Revenue CollaborationRevenue	200000	USD
	prta	Collaboration Revenue CollaborationRevenue	600000	USD
CY2020Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2020Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	39921413	shares
CY2020Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	39921413	shares
	prta	Numberof Votes NumberofVotes	1	vote
CY2020Q3	prta	Deferred Shares Shares Authorized DeferredSharesSharesAuthorized	10000	shares
CY2020Q3	prta	Deferred Shares Par Value DeferredSharesParValue	22
CY2020Q3	prta	Deferred Shares Share Outstanding DeferredSharesShareOutstanding	0	shares
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	147000	shares
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	292500	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	1865950	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	1290475	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P4Y
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8795230	shares
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	20.97
CY2020Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	36800000	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y5M23D
CY2020Q3	us-gaap	Share Based Compensation ShareBasedCompensation	5583000	USD
CY2020Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
	us-gaap	Share Based Compensation ShareBasedCompensation	16806000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	18298000	USD
CY2019Q3	us-gaap	Share Based Compensation ShareBasedCompensation	5816000	USD
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.796
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.810
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.811
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.814
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.003
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.018
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.010
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.023
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	21336	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	9.42
CY2019Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	8.56
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	7.09
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	8.22
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	8.61
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7008403	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	23.34
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y2M26D
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	11901000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	1865950	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	11.94
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	22852	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	34935	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	13.18
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	33.61
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8795230	shares
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	20.97
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y4M13D
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1994000	USD
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	8378260	shares
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	21.34
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P7Y25D
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	1986000	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	4859859	shares
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	25.93
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y3M3D
CY2020Q3	prta	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value Related To Vested Options ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueRelatedToVestedOptions	1918000	USD
CY2020Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-215000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-636000	USD
CY2019Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	468000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	510000	USD
CY2020Q3	prta	Sharebased Compensation Net Tax Shortfall Excess Tax Benefit Amount Bookedto Income Tax Provision SharebasedCompensationNetTaxShortfallExcessTaxBenefitAmountBookedtoIncomeTaxProvision	0	USD
	prta	Sharebased Compensation Net Tax Shortfall Excess Tax Benefit Amount Bookedto Income Tax Provision SharebasedCompensationNetTaxShortfallExcessTaxBenefitAmountBookedtoIncomeTaxProvision	100000	USD
CY2019Q3	prta	Sharebased Compensation Net Tax Shortfall Excess Tax Benefit Amount Bookedto Income Tax Provision SharebasedCompensationNetTaxShortfallExcessTaxBenefitAmountBookedtoIncomeTaxProvision	900000	USD
	prta	Sharebased Compensation Net Tax Shortfall Excess Tax Benefit Amount Bookedto Income Tax Provision SharebasedCompensationNetTaxShortfallExcessTaxBenefitAmountBookedtoIncomeTaxProvision	1900000	USD

Files In Submission

Name	View Source	Status
0001559053-20-000040-index-headers.html	Edgar Link	pending
0001559053-20-000040-index.html	Edgar Link	pending
0001559053-20-000040.txt	Edgar Link	pending
0001559053-20-000040-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
prta-20200930.htm	Edgar Link	pending
prta-20200930.xsd	Edgar Link	pending
prta-20200930_cal.xml	Edgar Link	unprocessable
prta-20200930_def.xml	Edgar Link	unprocessable
prta-20200930_htm.xml	Edgar Link	completed
prta-20200930_lab.xml	Edgar Link	unprocessable
prta-20200930_pre.xml	Edgar Link	unprocessable
prta2020q310-qxex311.htm	Edgar Link	pending
prta2020q310-qxex312.htm	Edgar Link	pending
prta2020q310-qxex321.htm	Edgar Link	pending
prta2020q3xex1013rdame.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PRTA
PROTHENA CORP PUBLIC LTD CO Stock $prta

2020 Q4 Form 10-Q Financial Statement

#000155905320000040 Filed on November 04, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PRTA PROTHENA CORP PUBLIC LTD CO Stock $prta

2020 Q4 Form 10-Q Financial Statement

#000155905320000040 Filed on November 04, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PRTA
PROTHENA CORP PUBLIC LTD CO Stock $prta